This study investigates the safety and tolerability of an investigational medication that may delay the onset or slow the progression of Alzheimer's disease (AD). Alzheimer's disease is a brain disorder that affects memory and thinking skills. The study will examine how the medication affects protein levels in the cerebrospinal fluid (CSF) and blood, which are associated with AD.
Participants will undergo procedures including lumbar punctures, also known as spinal taps, to collect cerebrospinal fluid. The study will measure the amount of the investigational medication in the CSF and blood to understand its effects on Alzheimer's-related proteins.
- Who can participate: Adults with mild cognitive impairment or probable mild Alzheimer's disease, who have at least 6 years of education and good general health, can participate. Female participants must be post-menopausal or surgically sterile, and all participants must speak English fluently and have a study partner.
- Study details: Participants will take multiple doses of an investigational medication over 23-25 days. A placebo, an inactive substance, may be used. Participants will undergo spinal taps to collect cerebrospinal fluid.
How understandable was the trial content above?
Hard to understand
Easy to understand
